CDK4/6-targeted therapy for gastrointestinal cancers: from resistance mechanisms to immuno-combination strategies guided by biomarkers - Top-Institutions - MDSpire

Targeting CDK4/6 in Gastrointestinal Malignancies: Exploring Resistance Mechanisms and Biomarker-Driven Immunotherapy Combinations

  • By

  • Junhao Cui

  • Yanchuan Zhang

  • Yongfang Wu

  • Guangjie Zhang

  • Jie Lan

  • Yingshuang Wang

  • June 4, 2026

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, Texas

    Key Differentiators

    • Oncology

  • #2

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, New York

    Key Differentiators

    • Oncology

Original Source(s)

CDK4/6-targeted therapy for gastrointestinal cancers: from resistance mechanisms to immuno-combination strategies guided by biomarkers

  • by Junhao Cui, Yanchuan Zhang, Yongfang Wu, Guangjie Zhang, Jie Lan, Yingshuang Wang

  • June 4, 2026

Related Content

Treatment patterns and outcomes of patients with a diagnosis of metastatic pancreatic adenocarcinoma in the United States, 2019–2024

Vitiligo-like depigmentation following neoadjuvant chemotherapy combined with pembrolizumab in early triple-negative breast cancer: a case report

Impact of high-fat Western diet on chronic lymphocytic leukemia disease progression and gut microbiome profile in Eµ-TCL1 mice